foxo4 dri senolytic peptide human trial 2024 2025 FOXO4-DRI UK | Research Senescent cells as a target

maintenance phase is the heavy draw 26 weeks 13 vials Standard Phase 2 duration 32 weeks 16 vials Phase 2 T2D study duration 68 weeks 30 vials REDEFINE 1 / REDEFINE 2 endpoint duration Peptide Vials (10 mg vial, 2.4 mg/week target) Each 10 mg vial covers about 4 weekly doses at 2.4 mg/week

GMP certified / 99% HPLC purity / Pan-India delivery / Cash on Delivery available Research Use Only This product is intended solely for laboratory and research purposes

Studies indicate that GHK-Cu may stimulate the production of collagen types I, III, and V, as well as elastin, decorin, and glycosaminoglycans in fibroblast cell cultures

The peptide also promotes polarization of macrophages from pro-inflammatory M1 phenotypes toward tissue-repairing M2 phenotypes, with treated macrophages showing 70% increased phagocytic activity for clearing inflammatory debris and 3-fold higher production of VEGF compared to untreated controls